香港交易及結算所有限公司及香港聯合交易所有限公司對本通告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 通 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 Pharma Corporation Jacobson Pharma Corporation Limited 雅 各 臣 科 研 製 藥 有 限 公 司 （股份代號：2633） 股東週年大會通告 茲通告 雅各臣科研製藥有限公司（「本公司」）謹訂於二零二五年七月二十八日 （星 期 一）下午三時正通過虛擬會議舉行股東週年大會（「股東週年大會」），議 程 如 下： – 1 – 1. 省 覽、考 慮 及 批 准 本 公 司 截 至 二 零 二 五 年 三 月 三 十 一 日 止 年 度 的 經 審 核 綜 合 財 務 報 表 及 董 事 報 告 書 與 獨 立 核 數 師 報 告。 2. 宣派截至二零二五年三月三十一日止年度的末期股息每股5.50港 仙。 3. 宣派截至二零二五年三月三十一日止年度的特別股息每股6.00港 仙。 4. 重 選 岑 廣 業 先 ...

此乃要件 請即處理 閣下如 對本通函任何方面或應採取的行動 有任何疑問，應諮詢股票經紀或其他持牌證券 交易商、銀行經理、律師、專業會計師或其他專業顧問。 閣下如已售出或轉讓 名下所有雅各臣科研製藥有限公司的股份，應立即將本通函連同隨 附的代表委任表格交予買主或承讓人、或經手買賣或轉讓的銀行、股票經紀或其他代理商， 以便轉交買主或承讓人。 香港交易及結算所有限公司及香港聯合交易所有限公司對本通函的內容概不負責，對其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 通 函 全 部 或 任 何 部 分 內 容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Pharma Corporation Jacobson Pharma Corporation Limited 雅 各 臣 科 研 製 藥 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：2633） 建議重選董事 及 建議授出購回股份以及發行股份及 出售庫存股份的 一般授權 以 及 股東週年大會通告 雅各臣科研製藥有限公司謹訂於二零二五年七月二十八日（星期一）下午三時正透過Vistra 卓佳電 ...

Company Information [Company Information](index=3&type=section&id=%E5%85%AC%E5%8F%B8%E8%B3%87%E6%96%99) Provides fundamental details about the company Financial Summary [Financial Summary](index=4&type=section&id=%E8%B2%A1%E5%8B%99%E6%91%98%E8%A6%81) The group achieved robust growth in revenue and profit, with improved margins and stable financial health Key Financial Indicators for FY2025 (thousand HKD) | Indicator | Year Ended March 31, 2025 (thousand HKD) | Year Ended March 31, 2024 (thousand HKD) | Change | | :--- | :--- | :--- | :--- | | **Revenue from Continuing Operations** | 1,576,897 | 1,467,798 | +7.4% | | **Gross Profit** | 692,939 | 620,475 | +11.7% | | Gross Margin | 43.9% | 42.3% | - | | **Profit Attributable to Equity Holders** | 300,833 | 266,968 | +12.7% | | Profit Margin Attributable to Equity Holders | 19.1% | 18.2% | - | | **Adjusted EBITDA from Continuing Operations** | 572,765 | 453,071 | +26.4% | | Adjusted EBITDA Margin from Continuing Operations | 36.3% | 30.9% | - | | **Return on Equity** | 12.3% | 10.3% | - | | **Total Assets** | 3,645,162 | 3,486,854 | +4.5% | | **Total Equity** | 2,477,439 | 2,396,360 | +3.4% | Chairman's Report [Chairman's Report](index=6&type=section&id=%E4%B8%BB%E5%B8%AD%E5%A0%B1%E5%91%8A) Highlights resilient growth, robust financial performance, R&D expansion, and strategic transformation in FY2025 - FY2025 performance robust, revenue grew **7.4%** to **HK$1,576.9 million**, annual profit from continuing operations surged **43.1%** to **HK$300.8 million**[20](index=20&type=chunk) - Company R&D pipeline expanded with **219 products** in various development stages, preparing for future market demand[21](index=21&type=chunk) - Breakthroughs in innovative therapies, including oral Arsenol for acute promyelocytic leukemia co-developed with the University of Hong Kong, and CAR-T therapy Yikaida launched in collaboration with Fosun Pharma[23](index=23&type=chunk) - To expand capacity, the company acquired a pharmaceutical facility in Tai Po InnoPark, planning to equip **ten smart production lines** with trial production expected by the end of 2026[25](index=25&type=chunk) Corporate Vision and Mission [Corporate Vision and Mission](index=8&type=section&id=%E4%BC%81%E6%A5%AD%E9%A1%98%E6%99%AF%E5%8F%8A%E4%BD%BF%E5%91%BD) Outlines the company's long-term goals and core values Company Profile [Company Profile](index=9&type=section&id=%E5%85%AC%E5%8F%B8%E7%B0%A1%E4%BB%8B) Presents an overview of the company's business and operations Management Discussion and Analysis [Business Review](index=11&type=section&id=%E6%A5%AD%E5%8B%99%E5%9B%9E%E9%A1%A7) The Group achieved robust performance in FY2025, driven by market demand and strategic initiatives - Market demand increased due to high influenza incidence, aging population, rising chronic disease prevalence, and enhanced public health awareness[47](index=47&type=chunk) - The Group advanced sustainable development through the "Five Constants Development" framework, achieving significant progress and recognition in environmental, social, and governance aspects[48](index=48&type=chunk) [Performance](index=11&type=section&id=%E6%A5%AD%E7%B8%BE) Total revenue grew 7.4% to HK$1,576.9 million, with profit from continuing operations surging 43.1% FY2025 Performance Overview (million HKD) | Indicator | Amount (million HKD) | Year-on-Year Growth | | :--- | :--- | :--- | | Total Revenue | 1,576.9 | +7.4% | | Profit for the Year from Continuing Operations | 300.8 | +43.1% | | Profit Attributable to Equity Holders | 300.8 | +12.7% | | Adjusted EBITDA | 572.8 | - | - Net gearing ratio improved from **12.2% to 8.3%**, with cash reserves maintained at **HK$509.0 million**, indicating a solid financial foundation[50](index=50&type=chunk) [Operating Performance](index=12&type=section&id=%E7%B6%93%E7%87%9F%E8%A1%A8%E7%8F%BE) Strong operating performance driven by product portfolio, R&D, expanded capacity, and business development [Robust Product Portfolio](index=12&type=section&id=%E5%BC%B7%E5%A4%A7%E7%94%A2%E5%93%81%E7%B5%84%E5%90%88) High market demand for pharmaceuticals led to strong growth across key therapeutic categories - Strong growth momentum recorded in **cardiovascular**, **oral anti-diabetic**, and **bladder and prostate** drug segments[53](index=53&type=chunk) [R&D Pipeline](index=12&type=section&id=%E7%A0%94%E7%99%BC%E7%94%A2%E5%93%81%E7%B7%9A) The R&D pipeline includes 219 products, with 13 submitted for registration across various therapeutic areas R&D Pipeline Status (as of March 31, 2025) | Stage | Number of Products | | :--- | :--- | | Registered and Approved | 65 | | Under Registration Review | 13 | | Development Completed (Stability Preparation/Testing) | 63 | | In Formulation/Pre-Formulation Study | 22 | | **Total** | **219** | [Expanded Production and Enhanced Smart Capacity](index=13&type=section&id=%E6%93%B4%E5%A4%A7%E7%94%A2%E7%94%A2%E5%8F%8A%E6%8F%90%E9%AB%98%E6%99%BA%E8%83%BD%E5%8C%96%E7%94%A2%E8%83%BD) Production capacity increased, with a new smart facility acquired for future manufacturing - Sterile eye drops production increased by **23.3%** year-on-year to approximately **45,600 liters**[59](index=59&type=chunk) - Acquired a dedicated pharmaceutical facility in Tai Po InnoPark, to be expanded to over **70,000 square feet** with **10 new smart production lines**[59](index=59&type=chunk) [Business Development](index=13&type=section&id=%E6%A5%AD%E5%8B%99%E7%99%BC%E5%B1%95) Business expanded through in-licensing, strategic collaborations, and digital transformation initiatives - In-licensed **20 high-efficacy specialty drugs** across rheumatology, oncology, and cardiology[61](index=61&type=chunk) - Oral arsenic therapy Arsenol, co-developed with HKU, received US FDA IND approval, with global Phase III clinical trials planned for **2026**[63](index=63&type=chunk) - Successfully launched Hong Kong's first CAR-T therapy Yikaida treatment and became one of the first operators to obtain an Advanced Therapy Product (ATP) logistics handling license[65](index=65&type=chunk) - Integrated e-business platform "e-MedLink" gained popularity among private clinic clients, streamlining drug procurement processes[69](index=69&type=chunk) [Outlook](index=15&type=section&id=%E5%B1%95%E6%9C%9B) Confident in Hong Kong's pharmaceutical market growth, driven by policy reforms and demographic shifts - Hong Kong government's expansion of the Chronic Disease Co-Care Pilot Scheme (CDCC) and plans to establish the Hong Kong Centre for Drug and Medical Device Regulation are expected to accelerate drug registration and boost demand for generic drugs[73](index=73&type=chunk)[74](index=74&type=chunk) - Aging population and increasing mental health issues will continue to stimulate demand for chronic disease treatments and psychotropic drugs[74](index=74&type=chunk) [Corporate Development](index=16&type=section&id=%E5%85%AC%E5%8F%B8%E7%99%BC%E5%B1%95) Acquired a new pharmaceutical facility in Tai Po InnoPark for capacity expansion and smart manufacturing - Successfully acquired a dedicated pharmaceutical facility in Tai Po InnoPark, spanning over **70,000 square feet**, to be equipped with **ten smart production lines**[77](index=77&type=chunk) - New facility will integrate AI, real-time data analytics, and robotics, with the first production line expected to commence trial production by **late 2026**[77](index=77&type=chunk) [Remuneration Policy](index=16&type=section&id=%E8%96%AA%E9%85%AC%E6%94%BF%E7%AD%96) Details employee numbers, total costs, remuneration structure, and benefits as of March 31, 2025 Employee and Remuneration Overview (million HKD) | Indicator | March 31, 2025 | March 31, 2024 | | :--- | :--- | :--- | | Number of Employees | 1,749 | 1,723 | | Total Employee Costs (million HKD) | 473.1 | 452.1 | [Financial Review](index=17&type=section&id=%E8%B2%A1%E5%8B%99%E5%9B%9E%E9%A1%A7) Robust financial performance with 7.4% revenue growth and 12.7% increase in profit attributable to equity holders [Revenue](index=17&type=section&id=%E6%94%B6%E7%9B%8A) Group revenue grew 7.4% to HK$1,576.9 million, primarily from specialty and generic drugs in Hong Kong Revenue Overview (million HKD) | Indicator | FY2025 (million HKD) | FY2024 (million HKD) | Year-on-Year Growth | | :--- | :--- | :--- | :--- | | Total Revenue | 1,576.9 | 1,467.8 | +7.4% | Revenue by Region (FY2025) (million HKD) | Region | Revenue (million HKD) | Percentage | | :--- | :--- | :--- | | Hong Kong | 1,514.6 | 96% | | Mainland China | 34.6 | 2% | | Macau | 27.6 | 2% | | Other | 0.1 | 0% | | **Total** | **1,576.9** | **100%** | [Cost of Sales](index=19&type=section&id=%E9%8A%B7%E5%94%AE%E6%88%90%E6%9C%AC) Cost of sales increased 4.3% to HK$884.0 million, aligned with sales growth, driven by material and staff costs Cost of Sales Composition (FY2025) (million HKD) | Cost Item | Amount (million HKD) | Percentage | | :--- | :--- | :--- | | Material Costs | 382.7 | 43% | | Staff Costs | 297.9 | 34% | | Other Production Costs | 203.4 | 23% | | **Total** | **884.0** | **100%** | [Operating Profit, Finance Costs, and Income Tax](index=20&type=section&id=%E7%B6%93%E7%87%9F%E6%BA%A2%E5%88%A9%E3%80%81%E8%9E%8D%E8%B3%87%E6%88%90%E6%9C%AC%E5%8F%8A%E6%89%80%E5%BE%97%E7%A8%85) Operating profit rose 24.5% to HK$414.6 million, with finance costs significantly reduced - Operating profit increased by **24.5%** to **HK$414.6 million**[91](index=91&type=chunk)[92](index=92&type=chunk) - Finance costs significantly decreased by **47.4%**, primarily due to bank loan repayments and lower market interest rates[93](index=93&type=chunk) [Profit Attributable to Equity Holders](index=21&type=section&id=%E6%AC%8A%E7%9B%8A%E6%8C%81%E6%9C%89%E4%BA%BA%E6%87%89%E4%BD%B5%E6%BA%A2%E5%88%A9) Profit attributable to equity holders increased 12.7% to HK$300.8 million, driven by continuing operations Profit Attributable to Equity Holders (million HKD) | Indicator | FY2025 (million HKD) | FY2024 (million HKD) | Year-on-Year Growth | | :--- | :--- | :--- | :--- | | Profit Attributable to Equity Holders | 300.8 | 267.0 | +12.7% | [Assets and Liabilities](index=21&type=section&id=%E8%B3%87%E7%94%A2%E8%88%87%E8%B2%A0%E5%82%B5) Property, plant, and equipment increased, while goodwill impairment tests showed no impairment - The estimated recoverable amount of the generic drug segment's cash-generating unit exceeded its carrying amount by approximately **HK$1,268.3 million**, with no goodwill impairment identified[99](index=99&type=chunk) [Use of Proceeds](index=22&type=section&id=%E6%89%80%E5%BE%97%E6%AC%BE%E9%A0%85%E7%94%A8%E9%80%94) IPO and share placement proceeds of HK$734.4 million were fully utilized for acquisitions and investments - Proceeds of **HK$695.5 million** from the IPO and **HK$38.9 million** from the share placement were fully utilized as of March 31, 2025[105](index=105&type=chunk)[106](index=106&type=chunk) [Liquidity, Capital Resources, and Equity Structure](index=23&type=section&id=%E6%B5%81%E5%8B%95%E8%B3%87%E9%87%91%E3%80%81%E8%B3%87%E6%9C%AC%E8%B3%87%E6%BA%90%E5%8F%8A%E8%82%A1%E6%9C%AC%E7%B5%90%E6%A7%8B) Strong financial position with net gearing ratio improving from 12.2% to 8.3% - Net gearing ratio decreased from **12.2% to 8.3%**, indicating an improved financial leverage level[110](index=110&type=chunk) Corporate Governance Report [Board and Committees](index=24&type=section&id=%E8%91%A3%E4%BA%8B%E6%9C%83%E8%88%87%E5%A7%94%E5%93%A1%E6%9C%83) The Board and its five committees oversee governance, ensuring compliance and diversity - The company complied with all code provisions of the Corporate Governance Code during the reporting period, except for the provision separating the roles of Chairman and Chief Executive Officer[117](index=117&type=chunk)[124](index=124&type=chunk) - The Board has established an Audit Committee, Remuneration Committee, Nomination Committee, Executive Committee, and Environmental, Social and Governance Committee to oversee specific governance matters[138](index=138&type=chunk) Gender Diversity of Board and Senior Management | Level | Female Percentage | Male Percentage | | :--- | :--- | :--- | | Board | 14.29% (1 person) | 85.71% (6 persons) | | Senior Management* | 14.29% (1 person) | 85.71% (6 persons) | | Other Employees | 42.25% (736 persons) | 57.75% (1,006 persons) | *Senior management includes directors only [Policies and Functions](index=32&type=section&id=%E6%94%BF%E7%AD%96%E8%88%87%E8%81%B7%E8%83%BD) The company adopted policies for director nomination and dividends, balancing returns with growth - The company adopted a Director Nomination Policy, specifying that candidates are evaluated across character, qualifications, diversity, and independence[161](index=161&type=chunk)[164](index=164&type=chunk) - The company adopted a Dividend Policy, aiming to distribute reasonable, stable, and consistent dividends while retaining sufficient reserves for future growth[166](index=166&type=chunk) [Accountability and Audit](index=34&type=section&id=%E5%95%8F%E8%B2%AC%E6%80%A7%E5%8F%8A%E5%AF%A9%E6%A0%B8) Emphasizes accountability, with a "three lines of defense" risk management framework and external audit - The company established a "three lines of defense" risk management framework (operational management, risk management function, internal audit), with the Board bearing overall responsibility for its effectiveness[175](index=175&type=chunk)[176](index=176&type=chunk)[177](index=177&type=chunk) - The Board reviewed the risk management and internal control systems for the year ended March 31, 2025, deeming them effective and adequate[184](index=184&type=chunk) Auditor's Remuneration (for the year ended March 31, 2025) (HKD) | Service Type | KPMG (HKD) | Other External Consultants (HKD) | | :--- | :--- | :--- | | Audit Services | 4,880,000 | - | | Non-Audit Services | 1,642,000 | 348,000 | [Shareholder Rights and Communication](index=36&type=section&id=%E8%82%A1%E6%9D%B1%E6%AC%8A%E5%88%A9%E8%88%87%E6%BA%9D%E9%80%9A) The company prioritizes shareholder communication through various channels and policies - Shareholders holding not less than **one-tenth of the company's voting rights** are entitled to request an extraordinary general meeting[192](index=192&type=chunk) - The company has established a Shareholder Communication Policy and communicates with shareholders through various channels, including general meetings, the company website, and investor relations functions[190](index=190&type=chunk)[198](index=198&type=chunk)[199](index=199&type=chunk) Directors' Report [Business Review and Principal Risks](index=39&type=section&id=%E6%A5%AD%E5%8B%99%E5%9B%9E%E9%A1%A7%E8%88%87%E4%B8%BB%E8%A6%81%E9%A2%A8%E9%9A%AA) Outlines generic drug business, key risks, and management measures - The Group is primarily engaged in the development, production, marketing, and sales of **generic drugs**[205](index=205&type=chunk) - Principal risks include failure to comply with pharmaceutical regulations, unsuccessful M&A integration, delays in new product development, and product liability risks for defective products[211](index=211&type=chunk) [Results and Dividends](index=40&type=section&id=%E6%A5%AD%E7%B8%BE%E5%8F%8A%E8%82%A1%E6%81%AF) Board recommends a total annual cash dividend of HK 15.00 cents per share for FY2025 FY2025 Dividend Proposal (HK cents per share) | Dividend Type | Amount Per Share (HK cents) | | :--- | :--- | | Interim Cash Dividend | 3.50 | | Proposed Final Cash Dividend | 5.50 | | Proposed Special Cash Dividend | 6.00 | | **Total for the Year** | **15.00** | [Directors and Equity-Linked Agreements](index=41&type=section&id=%E8%91%A3%E4%BA%8B%E5%8F%8A%E8%82%A1%E6%AC%8A%E6%8E%9B%E9%89%8A%E5%8D%94%E8%AD%B0) Details director information, share option scheme, and share award scheme - A total of **20,400,000 award shares** were granted to directors and eligible employees under the Share Award Scheme during the reporting period[250](index=250&type=chunk) - As of the end of the reporting period, there were **no outstanding share options** under the Share Option Scheme[247](index=247&type=chunk) [Connected Transactions and Continuing Connected Transactions](index=51&type=section&id=%E9%97%9C%E9%80%A3%E4%BA%A4%E6%98%93%E8%88%87%E6%8C%81%E7%BA%8C%E9%97%9C%E9%80%A3%E4%BA%A4%E6%98%93) Discloses connected transactions with Health & Happiness Group and its subsidiaries - In November 2024, Europharm, an indirect wholly-owned subsidiary, acquired a total of **100,500 shares** in Lee Chung Shing Tong (Holdings) Limited for a total consideration of **HK$46,230,000**[261](index=261&type=chunk) - The Group has multiple continuing connected transactions with Health & Happiness Group, including logistics services, manufacturing services, and overseas sales administrative services, all subject to annual caps and regular review[267](index=267&type=chunk)[270](index=270&type=chunk)[274](index=274&type=chunk)[278](index=278&type=chunk) Independent Auditor's Report [Independent Auditor's Report](index=56&type=section&id=%E7%8D%A8%E7%AB%8B%E6%A0%B8%E6%95%B8%E5%B8%AB%E5%A0%B1%E5%91%8A) KPMG issued an unmodified opinion on the consolidated financial statements, with goodwill impairment as a key audit matter - The auditor issued an **unmodified audit opinion**, stating that the financial statements are true and fair[291](index=291&type=chunk) - A key audit matter was assessing the potential impairment of goodwill related to the generic drug business; the auditor evaluated management's methodology, key assumptions (e.g., revenue growth rate, gross margin, discount rate), and sensitivity analysis, finding no significant issues[293](index=293&type=chunk)[294](index=294&type=chunk)[295](index=295&type=chunk) Consolidated Financial Statements [Consolidated Statement of Profit or Loss and Other Comprehensive Income](index=60&type=section&id=%E7%B6%9C%E5%90%88%E6%90%8D%E7%9B%8A%E5%8F%8A%E5%85%B6%E4%BB%96%E5%85%A8%E9%9D%A2%E6%94%B6%E7%9B%8A%E8%A1%A8) Revenue from continuing operations grew 7.4% to HK$1,576.9 million, with profit attributable to equity holders up 12.7% Consolidated Statement of Profit or Loss Summary (thousand HKD) | Item (thousand HKD) | FY2025 | FY2024 | | :--- | :--- | :--- | | **Revenue (Continuing Operations)** | 1,576,897 | 1,467,798 | | **Gross Profit** | 692,939 | 620,475 | | **Operating Profit** | 414,600 | 333,126 | | **Profit for the Year from Continuing Operations** | 300,833 | 210,169 | | **Profit for the Year from Discontinued Operations** | – | 52,392 | | **Profit for the Year** | 300,833 | 290,778 | | **Profit Attributable to Equity Holders** | 300,833 | 266,968 | | **Basic Earnings Per Share (HK cents)** | 15.15 | 13.90 | [Consolidated Statement of Financial Position](index=62&type=section&id=%E7%B6%9C%E5%90%88%E8%B2%A1%E5%8B%99%E7%8B%80%E6%B3%81%E8%A1%A8) Total assets increased 4.5% to HK$3,645.2 million, with net assets up 3.4% Consolidated Statement of Financial Position Summary (thousand HKD) | Item (thousand HKD) | March 31, 2025 | March 31, 2024 | | :--- | :--- | :--- | | **Non-Current Assets** | 2,607,208 | 2,522,438 | | **Current Assets** | 1,037,954 | 964,416 | | **Total Assets** | 3,645,162 | 3,486,854 | | **Current Liabilities** | 553,140 | 372,843 | | **Non-Current Liabilities** | 614,583 | 717,651 | | **Total Liabilities** | 1,167,723 | 1,090,494 | | **Net Assets** | 2,477,439 | 2,396,360 | [Consolidated Statement of Cash Flows](index=64&type=section&id=%E7%B6%9C%E5%90%88%E7%8F%BE%E9%87%91%E6%B5%81%E9%87%8F%E8%A1%A8) Strong net cash inflow of HK$526.8 million from operating activities, with year-end cash at HK$509.0 million Consolidated Statement of Cash Flows Summary (thousand HKD) | Item (thousand HKD) | FY2025 | FY2024 | | :--- | :--- | :--- | | Net Cash Generated from Operating Activities | 526,777 | 484,363 | | Net Cash (Used in) / Generated from Investing Activities | (297,758) | 43,342 | | Net Cash Used in Financing Activities | (131,296) | (1,053,255) | | **Net Increase / (Decrease) in Cash and Cash Equivalents** | 97,723 | (525,550) | | **Cash and Cash Equivalents at Year-End** | 509,045 | 411,937 | [Notes to the Financial Statements](index=65&type=section&id=%E8%B2%A1%E5%8B%99%E5%A0%B1%E8%A1%A8%E9%99%84%E8%A8%BB) Provides detailed explanations of financial statements, including discontinued operations and dividend policy - The branded healthcare segment was classified as a discontinued operation for the year ended March 31, 2024, due to the spin-off of Health & Happiness by way of distribution in specie[307](index=307&type=chunk)[414](index=414&type=chunk)[536](index=536&type=chunk) - Goodwill impairment tests were based on a five-year financial forecast, using a **3% growth rate** and a **14%-16% discount rate**, with management believing no reasonable change in assumptions would lead to impairment[452](index=452&type=chunk)[453](index=453&type=chunk) - The Board recommended a final dividend of **HK 5.50 cents** per share and a special dividend of **HK 6.00 cents** per share[439](index=439&type=chunk) Group Properties [Group Properties](index=124&type=section&id=%E6%9C%AC%E9%9B%86%E5%9C%98%E7%89%A9%E6%A5%AD) Lists and describes the properties held by the Group Five-Year Financial Summary [Five-Year Financial Summary](index=125&type=section&id=%E4%BA%94%E5%B9%B4%E8%B2%A1%E5%8B%99%E6%91%98%E8%A6%81) Shows new highs in revenue and profit from continuing operations in FY2025 after divestment Five-Year Financial Summary (thousand HKD) | Year Ended March 31 | 2025 | 2024 | 2023 (Restated) | 2022 | 2021 | | :--- | :--- | :--- | :--- | :--- | :--- | | **Revenue** | 1,576,897 | 1,467,798 | 1,267,598 | 1,595,543 | 1,445,915 | | **Gross Profit** | 692,939 | 620,475 | 538,918 | 620,522 | 561,083 | | **Profit for the Year from Continuing Operations** | 300,833 | 210,169 | 207,369 | 187,705 | 186,305 | | **Profit for the Year** | 300,833 | 290,778 | 283,209 | 187,705 | 186,308 | | **Profit Attributable to Equity Holders** | 300,833 | 266,968 | 251,044 | 177,666 | 173,713 | | **Net Assets** | 2,477,439 | 2,396,360 | 3,256,522 | 2,957,965 | 2,860,109 | Glossary [Glossary](index=126&type=section&id=%E8%A9%9E%E5%BD%99) Provides definitions for key terms used in the report

EF001 | 發行人所發行上市權證/可轉換債券的相關信息 | | | --- | --- | | 發行人所發行上市權證/可轉換債券 | 不適用 | | 其他信息 | | | 其他信息 | 不適用 | | 發行人董事 | | | 於 本 公 告 日 期，董 事 會 由 執 行 董 事 岑 廣 業 先 生（亦 為 主 席 兼 行 政 總 裁）、嚴 振 亮 先 生 及 潘 裕 慧 女 士；非 執 行 董 | | | 事 黃 志 基 教 授；及 獨 立 非 執 行 董 事 林 烱 堂 醫 生、楊 俊 文 先 生 及 林 誠 光 教 授 組 成。 | | 第 2 頁 共 2 頁 v 1.1.1 第 1 頁 共 2 頁 v 1.1.1 | EF001 | | --- | 免責聲明 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | --- | --- | | 股票發行人現金股息公告 | | | 發行人名稱 | 雅各臣科研製藥有限公司 | | 股份代號 ...

EF001 EF001 免責聲明 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 | | | --- | --- | | 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | 股票發行人現金股息公告 | | | 發行人名稱 | 雅各臣科研製藥有限公司 | | 股份代號 | 02633 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至二零二五年三月三十一日止年度的末期股息 | | 公告日期 | 2025年6月13日 | | 公告狀態 | 新公告 | | 股息信息 | | | 股息類型 | 末期 | | 股息性質 | 普通股息 | | 財政年末 | 2025年3月31日 | | 宣派股息的報告期末 | 2025年3月31日 | | 宣派股息 | 每 股 0.055 HKD | | 股東批准日期 | 2025年7月28日 | | 香港過戶登記處相關信息 | | | 派息金額及公司預設派發貨幣 | 每 股 0.055 HKD | | 匯率 ...

Financial Performance - For the fiscal year ending March 31, 2025, revenue from continuing operations was approximately HKD 1,576.9 million, an increase of about 7.4% compared to HKD 1,467.8 million in the same period of 2024[3]. - Operating profit from continuing operations for the same fiscal year was approximately HKD 414.6 million, representing a 24.5% increase from HKD 333.1 million in 2024[3]. - Profit from continuing operations for the year was approximately HKD 300.8 million, up 43.1% from HKD 210.2 million in the previous year[3]. - The total comprehensive income for the year was HKD 201.2 million, compared to HKD 271.9 million in the previous year[8]. - Basic earnings per share from continuing operations increased to HKD 15.15 from HKD 10.95 in the previous year[8]. - The group reported external customer revenue of HKD 1,576,897,000 for the year ending March 31, 2025, representing an increase from HKD 1,467,798,000 in the previous year, which is a growth of approximately 7.5%[23]. - The group’s consolidated profit before tax for the continuing operations was HKD 373,626,000 for the year ending March 31, 2025, compared to HKD 254,583,000 in the previous year, representing an increase of approximately 46.7%[25]. - Profit attributable to equity holders increased by HKD 33.8 million or 12.7% to HKD 300.8 million, mainly due to a substantial increase in profit from continuing operations[123]. Dividends - The board proposed a final cash dividend of HKD 5.50 per share and a special cash dividend of HKD 6.00 per share, totaling approximately HKD 230,025 million[3]. - The total cash dividend for the fiscal year ending March 31, 2025, is proposed to be HKD 15.00 per share, compared to HKD 5.50 per share in 2024[3]. - The company declared an interim dividend of HKD 3.50 per share for 2025, up from HKD 2.50 per share in 2024, representing a 40% increase[40]. - The final dividend for the fiscal year ending March 31, 2025, is HKD 3.00 per share, compared to HKD 2.38 per share for the previous year, totaling HKD 60,007,000 for the current year versus HKD 46,034,000 last year[43]. - The board of directors proposed a final cash dividend of HKD 5.50 per share for the fiscal year 2025, compared to HKD 3.00 per share for fiscal year 2024, and a special cash dividend of HKD 6.00 per share[150]. Assets and Liabilities - Non-current assets increased to HKD 2,607,208 thousand in 2025 from HKD 2,522,438 thousand in 2024, representing a growth of approximately 3.36%[9]. - Current assets rose to HKD 1,037,954 thousand in 2025, up from HKD 964,416 thousand in 2024, indicating an increase of about 7.63%[9]. - Total liabilities decreased to HKD 1,167,723 thousand in 2025 from HKD 1,090,494 thousand in 2024, reflecting a reduction of approximately 7.09%[10]. - The company's net asset value increased to HKD 2,477,439 thousand in 2025, compared to HKD 2,396,360 thousand in 2024, marking an increase of around 3.39%[10]. - Bank loans decreased significantly from HKD 592,200 thousand in 2024 to HKD 476,500 thousand in 2025, a reduction of approximately 19.58%[10]. - Trade receivables decreased to HKD 145,091,000 as of March 31, 2025, down from HKD 172,834,000 in the previous year, representing a decline of approximately 16%[44]. - Trade payables decreased to HKD 41,658,000 as of March 31, 2025, from HKD 51,688,000 in the previous year, reflecting a reduction of approximately 19%[46]. - Contract liabilities decreased significantly to HKD 24,167,000 from HKD 60,876,000, representing a decline of approximately 60%[46]. Research and Development - The company has 219 products at various stages of development, positioning itself well for future market demands[61]. - The total expenses for research and development (excluding capitalized development costs) were HKD 2,235,000 for the year ended March 31, 2025, down from HKD 6,450,000 in 2024, indicating a significant reduction[32]. - The company has a robust R&D pipeline with 219 products, including 65 approved, 13 under review, 63 completed development, and 22 in formulation research[84]. - The company has developed 13 products that have been submitted for registration approval, covering various therapeutic areas, including antipsychotics and cardiovascular medications[83]. Market and Product Development - The company has expanded its product portfolio by introducing 20 new high-impact specialty drugs, covering areas such as gastroenterology, oncology, and rare diseases[63]. - The company is strategically expanding its product portfolio and optimizing distribution channels to strengthen its market position in Hong Kong's non-specialty pharmaceutical sector[76]. - The company is expanding its market presence in Malaysia, Singapore, and Taiwan, with regulatory approvals and licensing agreements to accelerate market expansion[93]. - The company successfully launched Hong Kong's first Axicabtagene Ciloleucel (Yikaida) therapy on February 20, 2025, marking a significant milestone in advanced therapy[94]. - The company signed exclusive licensing agreements for 20 high-efficacy specialty drugs across various therapeutic areas, including rheumatology and oncology[88]. Financial Management - Financing costs decreased to HKD 41.4 million from HKD 78.7 million in the previous year, indicating improved financial management[5]. - The net debt-to-equity ratio improved from 12.2% to 8.3%, while cash reserves remained stable at HKD 509.0 million[78]. - The company has maintained a conservative financial management approach, ensuring a solid capital structure and financial strength for future business development and acquisitions[132]. - There were no significant contingent liabilities as of March 31, 2025, indicating a stable financial position[136]. Corporate Governance and Compliance - The financial statements were prepared in accordance with the Hong Kong Financial Reporting Standards, ensuring compliance with applicable disclosure requirements[12]. - The company has adhered to all applicable laws and regulations during the reporting period, ensuring compliance and governance[144]. - The company has successfully maintained high standards of corporate governance, enhancing shareholder value and corporate responsibility[145]. - The audit committee, consisting of three independent non-executive directors, is responsible for reviewing and supervising the group's financial reporting procedures and internal controls[148]. Sustainability and Corporate Responsibility - The company is committed to sustainable development, focusing on reducing greenhouse gas emissions and waste generation during the reporting period[74]. - The company has implemented various measures to encourage environmental protection and energy conservation, recognizing the importance of sustainable development[142]. - The company has received recognition for its corporate responsibility efforts, winning awards for being a good employer and an outstanding environmental partner[75]. Future Outlook - The company anticipates growth opportunities in the local pharmaceutical market due to recent policy reforms, including the Chronic Disease Collaborative Care Pilot Program and the establishment of the Hong Kong Medicines and Medical Devices Regulatory Authority[69]. - The company plans to launch three new products in the upcoming fiscal year, targeting a market expansion of 30%[158]. - The company has set a revenue guidance of HKD 1.5 billion for the next fiscal year, indicating a growth target of 25%[156]. - The government’s chronic disease management pilot program has benefited over 58,000 patients, promoting the use of non-prescription drugs in chronic disease management[100].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 Pharma Corporation Jacobson Pharma Corporation Limited 雅 各 臣 科 研 製 藥 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：2633） 林 教 授 已 確 認，彼 與 董 事 會 並 無 任 何 意 見 分 歧，亦 無 有 關 彼 退 任 的 其 他 事 宜 須 提 請 香 港 聯 合 交 易 所 有 限 公 司 及╱或 本 公 司 股 東 垂 注。 董事會謹此衷心感謝林教授自二零一六年四月起的任期內對本公司作出的寶 貴 貢 獻。 本 公 司 將 物 色 合 適 人 選 以 填 補 林 教 授 退 任 後 產 生 的 空 缺。 承董事會命 雅各臣科研製藥有限公司 公司秘書 余振球 香 港，二 零 二 五 年 六 月 十 三 日 於 本 公 告 日 期，董 事 會 由 執 行 ...

承董事會命 雅各臣科研製藥有限公司 Jacobson Pharma Corporation Limited 雅 各 臣 科 研 製 藥 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：2633） 董事會召開日期 雅各臣科研製藥有限公司（「本公司」）董事會（「董事會」）兹通告謹定於二零二五 年六月十三日（星 期 五）舉 行 董 事 會 會 議，藉 以 考 慮 及 通 過 本 公 司 及 其 附 屬 公 司 截 至 二 零 二 五 年 三 月 三 十 一 日 止 的 年 度 全 年 業 績 以 供 發 佈，並 考 慮 建 議 派 發 末期股息（如 有），以 及 處 理 其 他 事 項。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 Pharma Corporation 公司秘書 余振球 香 港，二 零 二 五 年 五 月 三 十 日 於 本 公 告 日 期，董 事 會 由 執 行 董 ...

Group 1 - As of May 26, a total of 88 stocks reached their 52-week highs, with Tianbao Energy (01671), China Nuclear International (02302), and Honghui Group (00183) leading the high rate at 141.60%, 93.92%, and 21.34% respectively [1] - Tianbao Energy closed at 0.700 and reached a peak of 1.510, marking a significant increase of 141.60% [1] - China Nuclear International closed at 4.090 with a highest price of 5.100, reflecting a rise of 93.92% [1] Group 2 - Other notable stocks that reached their 52-week highs include Century International (00959) with an increase of 18.64%, and Junjie Group Holdings (08188) with a rise of 17.95% [1] - The list also includes Haotian Financial Group (01260) with a 13.70% increase and Dechang Electric Holdings (00179) with a 10.96% rise [1] - The overall trend indicates a strong performance in the market, with multiple stocks achieving significant gains [1] Group 3 - The report also highlights stocks that reached their 52-week lows, with Sipai Health (00314) showing the largest decline at -11.65% [3] - Other stocks experiencing declines include Feitian Yundong (06610) at -9.05% and Hengrui Medicine (01276) at -4.81% [3] - The presence of stocks reaching both highs and lows suggests a volatile market environment [3]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 雅 各 臣 科 研 製 藥 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：2633） 盈喜預告 本公告由雅各臣科研製藥有限公司（「本公司」，連 同 其 附 屬 公 司 統 稱「本集團」） 根據香港聯合交易所有限公司證券上市規則（「上市規則」）第13.09(2)(a)條及香港 法例第571章證券及期貨條例第XIVA部項下內幕消息條文（定 義 見 上 市 規 則）刊 發。 本公司董事（「董 事」）會（「董事會」）謹此告知本公司股東（「股 東」）及 潛 在 投 資 者， 基於對本集團截至二零二五年三月三十一日止年度（「二零二五財年」）的未經審 核 綜 合 管 理 賬 目 的 初 步 審 閱 及 董 事 會 目 前 可 得 的 資 料，本 集 團 預 期，二 零 二 五 財年錄得來自持續經營業務的溢利較截至二零二四年三月三十一日止年度增 加 ...